CAJ | 학술논문

目的：观察柳氮磺胺吡啶联合益生菌治疗溃疡性结肠炎的临床疗效。方法52例溃疡性结肠炎患者随机分为两组，每组26例，对照组予柳氮磺吡啶1.0 g/次，4次/d，观察组联合益生菌500 mg/次，3次/d，疗程8周。比较两组患者临床疗效及治疗前后疾病活动指数(DAI)、血清白细胞介素-6(IL-6)、白细胞介素-8(IL-8)及肿瘤坏死因子-α(TNF-α)水平的变化。结果治疗后，观察组治疗总有效率为96.15%，明显高于对照组的76.92%，差异有统计学意义(P<0.05)；两组患者DAI评分均较治疗前显著下降，且观察组明显低于对照组，差异均有统计学意义(P<0.05)；两组患者血清IL-6、IL-8及TNF-α水平均较治疗前显著下降，且观察组上述指标水平明显低于对照组，差异均有统计学意义(P<0.05)。结论柳氮磺胺吡啶联合益生菌治疗轻、中度溃疡性结肠炎疗效明显优于单独使用柳氮磺胺吡啶，可进一步抑制患者炎症反应、改善临床症状。
목적：관찰류담광알필정연합익생균치료궤양성결장염적림상료효。방법52례궤양성결장염환자수궤분위량조，매조26례，대조조여류담광필정1.0 g/차，4차/d，관찰조연합익생균500 mg/차，3차/d，료정8주。비교량조환자림상료효급치료전후질병활동지수(DAI)、혈청백세포개소-6(IL-6)、백세포개소-8(IL-8)급종류배사인자-α(TNF-α)수평적변화。결과치료후，관찰조치료총유효솔위96.15%，명현고우대조조적76.92%，차이유통계학의의(P<0.05)；량조환자DAI평분균교치료전현저하강，차관찰조명현저우대조조，차이균유통계학의의(P<0.05)；량조환자혈청IL-6、IL-8급TNF-α수평균교치료전현저하강，차관찰조상술지표수평명현저우대조조，차이균유통계학의의(P<0.05)。결론류담광알필정연합익생균치료경、중도궤양성결장염료효명현우우단독사용류담광알필정，가진일보억제환자염증반응、개선림상증상。
Objective To evaluate the clinical efficacy of probiotics combined with sulfasalazine in the treat-ment of ulcerative colitis. Methods Fifty-two patients with ulcerative colitis were randomly divided into two groups, with 26 patients in each group. The control group was treated with sulfasalazine 1.0 g/times, 4 times/d, and the obser-vation group was treated with sulfasalazine combined with probiotics 500 mg/times, 3 times/d, eight weeks as a course. The clinical efficacy in the two groups, disease activity index (DAI), serum IL-6, IL-8 and TNF-α level changes were compared. Results After treatment, the total effective rate in the observation group was 96.15%, which was significantly higher than 76.92%in the control group (P<0.05). The DAI score in the two groups were both signif-icantly decreased compared with those before treatment, and the score was significantly lower in the observation group than the control group (P<0.05). The serum IL-6, IL-8 and TNF-αlevels in two groups were significantly de-creased, which was significantly lower in the observation group than the control group (P<0.05). Conclusion Probi-otics combined with sulfasalazine in the treatment of ulcerative colitis is better than sulfasalazine alone, and it can fur-ther suppress the inflammatory response, improve clinical symptoms.